|  | | Latest Updates | | | |  | Rapid ART Start, posted October 16, 2018. | | | | Doravirine--New NNRTI Approved by FDA, posted October 10, 2018. | | | | Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects, posted September 24, 2018. | | | | Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy, posted September 24, 2018. | | | | Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women, posted September 24, 2018. | | | | U=U in PARTNER2 Study of MSM, posted August 20, 2018. | | | | Dolutegravir + 3TC in Initial Therapy, posted August 20, 2018. | | | | Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study, posted August 20, 2018. | | | | Possible Safety Issue with Dolutegravir in Pregnancy: Reports of Neural Tube Defects, posted May 23, 2018. | | | | Bictegravir Approved for Initial ART, in Combination with TAF/FTC, posted April 11, 2018. | | | | Bictegravir/TAF/FTC for Women, posted April 11, 2018. | | | | Immediate ART Initiation Improves Time to Viral Suppression, posted April 11, 2018. | | | | Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir), posted April 11, 2018. | | | | Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study, posted April 11, 2018. | | | | Naltrexone Improves Virologic Suppression, posted April 11, 2018. | | | | Ibalizumab Approved for Persons with Multidrug Resistant HIV, posted April 11, 2018. | | | | Undetectable=Untransmittable: Effective HIV Treatment Prevents HIV Transmission, posted December 14, 2017. | |
|
| | Archive | | | | | On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen, posted September 28, 2017. | | | | Bictegravir in Initial Therapy, posted September 28, 2017. | | | | Doravirine in Initial Therapy: DRIVE-AHEAD Study, posted September 28, 2017. | | | | CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment, posted April 14, 2017. | | | | CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison, posted April 14, 2017. | | | | CROI 2017: Dolutegravir in 2-Drug Simplification Studies, posted April 14, 2017. | | | | CROI 2017: Failure of Dolutegravir Monotherapy, posted April 14, 2017. | | | | PrEP Uptake by Sex, Race, and Age, posted September 27, 2016. | | | | RAPID: Immediate ART Initiation, posted September 27, 2016. | | | | Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk; also a Word on HPTN 052, posted September 27, 2016. | | | | ART in Acute HIV--Decreasing HIV DNA, posted September 27, 2016. | | | | Improvements in ART and Viral Suppression Rates in the United States, posted September 27, 2016. | | | | HIV in Indiana, posted September 27, 2016. | | | | PrEP: Bone Density Improves after Stopping TDF/FTC, posted May 3, 2016. | | | | Use of Dolutegravir in Dialysis, posted May 3, 2016. | | | | TAF/FTC Coformulation Approved, posted April 26, 2016. | | | | Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy, posted April 11, 2016. | | | | Switching from TDF/FTC to TAF/FTC, posted March 17, 2016. | | | | Tissue Levels of TAF: Too Low for PrEP?, posted March 17, 2016. | | | | FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics, posted March 17, 2016. | |
|
|
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2019, Regents of the University of California.